Can AI remedy the growing pains of digital biomarker development?
AI implementation could be a useful tool to analyse generated data. Yet, regulatory approval hurdles are in sight.
By
Features (web)
Latest in
Features (web)
Back to the future: the evolution of clinical conference topics in the past decade
With the 20th birthday of the renowned Clinical Trial Supply East Coast conference in October, we look at topic changes…
By
Plaque psoriasis and psoriatic arthritis: trials to watch in 2022
Four Phase II and III trials in plaque psoriasis or psoriatic arthritis have results expected in 2H 2022, and five…
By
Rough diamonds: hiring Gen Z to become future clinical trial experts
Millennials and Gen Z can bring in fresh ideas but time and investment from hiring companies is required.
By
Internet of Things: a tsunami of clinical trial data
IoT devices allow sponsors to access an unprecedented volume and variety of data, but are they equipped to ride the…
By
Hepatitis B: can GSK’s bepirovirsen deliver functional cure?
GSK’s antisense oligonucleotide is looking to further prove its value in disrupting viral replication via a Phase III test.
By
Phase 0 clinical trials: what you need to know
Clinical Trials Arena breaks down the two most common types of Phase 0 trials, including window of opportunity trials in…
By
Glioblastoma: are Phase 0 trials a window of opportunity in drug development?
Despite key advantages to Phase 0 trials in glioblastoma, sponsors have been hesitant to employ the design.
By